Chicago – July 23: Lipitor tablets sit on a disc at a pharmacy of July 23, 2008 in Chicago, Illinois. … more
Congress considers the possibility of reducing the period of time protecting medicines. Stop and think about it.
Congress is currently with the tax code to “pay” the tax priorities of some members. This is the case as members of Congress who are working to extend the 2017 tax cuts and jobs law.
It is assumed that the course to its expansion includes “pay for it” by reducing patent protection for medicinal medicines. Something is very wrong with this picture.
To see why, it is useful to look at Revolution Medicine’s Daraxonrasib. The drug allows patients to survive one of the most consistent modern killers of all, pancreatic cancer. Away from Daraxonrasib’s Dostarlimab, Anaptysbio and Glaxosmithkline’s Dostarlimab make it possible for doctors to cure cancer without chemotherapy, radiation and cut off from infected organs.
What is important about this is that pioneers who develop critical medicines for patients are very much wanting to protect patents. Thus, while the wise minds can and will continue to discuss the value of patent protection, let’s forget about discussions for now and think of possible changes in the tax code with pharmacists.
Large pharmaceutical companies want to protect patents, given the huge costs associated with the development of life -enhancing drugs. This means that the reduction of the number of years of patent protection for the “payment” of other tax priorities is read as offensive and wronghead, regardless of one’s position to protect patents. Progress on the Health Front can stop more or less, because members of Congress have other tax cuts that want to “pay”?
The question should be asked simply because pharmaceutical companies see a reduction in patents are protected as significant costs, which would make it much more expensive to develop high chances of failure, but due to the latter they are highly likely to extend or save lives. Which is a reminder that the tax cut some in Congress want to pay to pay from others.
All of this requires us to rethink the way Congress sees the writing of the tax law. It must be clarified that tax cuts are When a cost. Such a view suggests that Congress exists as the well -intentioned source of the good, and that the good assumes that Dole Out is paid by it. No, no distance.
Congress is our result. Congress has capital and taxing power not because it is Congress, but because it has tax power to the American people it serves.
Consequently, whenever the Congress reduces the tax burden on individuals and businesses, there is no cost associated with it. How could it be? To indicate that it exists, and as Congress does, it is for the members who are elected to serve us to assume that we are working for them. No thank you. We are the ones who are responsible.
Since we are, the idea that Congress will possibly sacrifice the drug progress on the altar of “paid” tax cuts brings new meaning to the insult. Americans are also very taxed and suffering or dying very easily because medicines that could reduce their suffering and lengthen their lives do not yet exist. Let us not sacrifice a much better, much healthier future for the false idea that we are working for Congress and that reducing Congress’s weight is something that the people have to “pay”.
